T

Regulating Compound

Gene

Direction of Regulation (mRNA)

Fold Change

Direction of Regualtion (Protein)

Fold Change

Techniques

Dose

Time

Medium

Reference

Notes
TNF alpha AR (Androgen Receptor) No Change (Not Expressed) RT-PCR 200 U/mL 48 H RPMI-1640 + 10% FBS Cancer 77(9): 1862-72 at 80-90% confluence
TNF alpha c-myc No Change RT-PCR 200 U/mL 48 H RPMI-1640 + 10% FBS Cancer 77(9): 1862-72 at 80-90% confluence
TNF alpha CD-44 No Change (Not Expressed) FACS 200 U/mL 48 H RPMI-1640 + 10% FBS Cancer 77(9): 1862-72 at 80-90% confluence
TNF alpha Collagenase (Type IV) No Change RT-PCR 200 U/mL 48 H RPMI-1640 + 10% FBS Cancer 77(9): 1862-72 at 80-90% confluence
TNF alpha E-cadherin No Change RT-PCR 200 U/mL 48 H RPMI-1640 + 10% FBS Cancer 77(9): 1862-72 at 80-90% confluence
TNF alpha EGFR No Change RT-PCR 200 U/mL 48 H RPMI-1640 + 10% FBS Cancer 77(9): 1862-72 at 80-90% confluence
TNF alpha FGF2 (basic)

2X RT-PCR 200 U/mL 48 H RPMI-1640 + 10% FBS Cancer 77(9): 1862-72 at 80-90% confluence
TNF alpha Her-2 No Change RT-PCR 200 U/mL 48 H RPMI-1640 + 10% FBS Cancer 77(9): 1862-72 at 80-90% confluence
TNF alpha HLA Class I Antigen No Change FACS 200 U/mL 48 H RPMI-1640 + 10% FBS Cancer 77(9): 1862-72 at 80-90% confluence
TNF alpha HLA Class II Antigen No Change FACS 200 U/mL 48 H RPMI-1640 + 10% FBS Cancer 77(9): 1862-72 at 80-90% confluence
TNF alpha ICAM-1 No Change FACS 200 U/mL 48 H RPMI-1640 + 10% FBS Cancer 77(9): 1862-72 at 80-90% confluence
TNF alpha IL-6 No Change RT-PCR 200 U/mL 48 H RPMI-1640 + 10% FBS Cancer 77(9): 1862-72 at 80-90% confluence
TNF alpha Integrin alpha3

1.7X FACS 200 U/mL 48 H RPMI-1640 + 10% FBS Cancer 77(9): 1862-72 at 80-90% confluence
TNF alpha Integrin Beta1 No Change FACS 200 U/mL 48 H RPMI-1640 + 10% FBS Cancer 77(9): 1862-72 at 80-90% confluence
TNF alpha P-cadherin

2.5X RT-PCR 200 U/mL 48 H RPMI-1640 + 10% FBS Cancer 77(9): 1862-72 at 80-90% confluence
TNF alpha PSA (Prostate-Specific Antigen) No Change (Not Expressed) RT-PCR 200 U/mL 48 H RPMI-1640 + 10% FBS Cancer 77(9): 1862-72 at 80-90% confluence
TNF alpha PSM (Prostate-Specific Membrane) No Change (Not Expressed) RT-PCR 200 U/mL 48 H RPMI-1640 + 10% FBS Cancer 77(9): 1862-72 at 80-90% confluence
TNF alpha TGF beta No Change RT-PCR 200 U/mL 48 H RPMI-1640 + 10% FBS Cancer 77(9): 1862-72 at 80-90% confluence
troglitazone CD36 (oxidized LDL R) No Change None Western, Immunohistochemistry 10 uM 4 days DMEM + 10% FCS Cancer Res 58(15): 3344-52
troglitazone E-cadherin No Change None Western, Immunohistochemistry 10 uM 4 days DMEM + 10% FCS Cancer Res 58(15): 3344-52
troglitazone PPARgamma No Change None Western, Immunohistochemistry 10 uM 4 days DMEM + 10% FCS Cancer Res 58(15): 3344-52
troglitazone, all-trans-retinoic acid CD36 (oxidized LDL R) No Change None Western, Immunohistochemistry 10 uM/100 nM 4 days DMEM + 10% FCS Cancer Res 58(15): 3344-52
troglitazone, all-trans-retinoic acid E-cadherin No Change None Western, Immunohistochemistry 10 uM/100 nM 4 days DMEM + 10% FCS Cancer Res 58(15): 3344-52
troglitazone, all-trans-retinoic acid PPARgamma No Change None Western, Immunohistochemistry 10 uM/100 nM 4 days DMEM + 10% FCS Cancer Res 58(15): 3344-52
troglitazone, LG100268 CD36 (oxidized LDL R) No Change None Western, Immunohistochemistry 10 uM/100 nM 4 days DMEM + 10% FCS Cancer Res 58(15): 3344-52
troglitazone, LG100268 E-cadherin No Change None Western, Immunohistochemistry 10 uM/100 nM 4 days DMEM + 10% FCS Cancer Res 58(15): 3344-52
troglitazone, LG100268 PPARgamma No Change None Western, Immunohistochemistry 10 uM/100 nM 4 days DMEM + 10% FCS Cancer Res 58(15): 3344-52